Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

Author's Avatar
Jul 11, 2022

Positive top-line results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma announced in January 2022; BLA submission expected in 2022